Immunotherapies in Ovarian Cancer

Overview

Journal EJC Suppl

Specialty Oncology

Date 2020 Nov 26

PMID 33240447

Citations 3

Authors

Elena Garcia-Martinez

J Alejandro Perez-Fidalgo

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherapy is not yet incorporated to the armamentarium in ovarian cancer. This review briefly summarises the strategies that have been tested or are under study for the three different groups of tumours: immune desert, inflamed and immune-excluded ovarian tumours. Finally, a better knowledge of the biology and immune microenvironment is needed for successfully developing new immunotherapy strategies.

Citing Articles

Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics.

Balan D, Kampan N, Plebanski M, Abd Aziz N Front Oncol. 2024; 14:1388663.

PMID: 38873253 PMC: 11169633. DOI: 10.3389/fonc.2024.1388663.

Analysis of the Polymorphisms and Expression Levels of the BCL2, BAX and c-MYC Genes in Patients with Ovarian Cancer.

Olbromski P, Bogacz A, Bukowska M, Kaminski A, Moszynski R, Pawlik P Int J Mol Sci. 2023; 24(22).

PMID: 38003498 PMC: 10671037. DOI: 10.3390/ijms242216309.

Successful secondary radical operation on unretractable metastatic platinum-sensitive recurrent ovarian cancer by immunotherapy: a case report.

Sun L, Li H, Wei S, Yang M, Deng S Ann Transl Med. 2022; 10(12):718.

PMID: 35845511 PMC: 9279770. DOI: 10.21037/atm-22-2128.

References

Martin Lluesma S, Wolfer A, Harari A, Kandalaft L . Cancer Vaccines in Ovarian Cancer: How Can We Improve?. Biomedicines. 2017; 4(2). PMC: 5344251. DOI: 10.3390/biomedicines4020010. View

Lee J, Cimino-Mathews A, Peer C, Zimmer A, Lipkowitz S, Annunziata C . Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A.... J Clin Oncol. 2017; 35(19):2193-2202. PMC: 5493052. DOI: 10.1200/JCO.2016.72.1340. View

Wolf D, Wolf A, Rumpold H, Fiegl H, Zeimet A, Muller-Holzner E . The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005; 11(23):8326-31. DOI: 10.1158/1078-0432.CCR-05-1244. View

Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M . Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther. 2011; 20(3):679-86. PMC: 3293620. DOI: 10.1038/mt.2011.269. View

Torphy R, Schulick R, Zhu Y . Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. Int J Mol Sci. 2017; 18(12). PMC: 5751245. DOI: 10.3390/ijms18122642. View

Smith M, Garcia-Martinez E, Pitter M, Fucikova J, Spisek R, Zitvogel L . Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology. 2018; 7(12):e1526250. PMC: 6279325. DOI: 10.1080/2162402X.2018.1526250. View

Dijkgraaf E, Welters M, Nortier J, van der Burg S, Kroep J . Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des. 2012; 18(25):3816-27. DOI: 10.2174/138161212802002797. View

DIncalci M, Galmarini C . A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010; 9(8):2157-63. DOI: 10.1158/1535-7163.MCT-10-0263. View

Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T . Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010; 107(17):7875-80. PMC: 2867907. DOI: 10.1073/pnas.1003345107. View

10.

Zang X, Sullivan P, Soslow R, Waitz R, Reuter V, Wilton A . Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010; 23(8):1104-12. PMC: 2976590. DOI: 10.1038/modpathol.2010.95. View

11.

James F, Jiminez-Linan M, Alsop J, Mack M, Song H, Brenton J . Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer. 2017; 17(1):657. PMC: 5607562. DOI: 10.1186/s12885-017-3585-x. View

12.

Kobayashi M, Chiba A, Izawa H, Yanagida E, Okamoto M, Shimodaira S . The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. J Ovarian Res. 2014; 7:48. PMC: 4108140. DOI: 10.1186/1757-2215-7-48. View

13.

Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I . Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7):1080-1087. DOI: 10.1093/annonc/mdz135. View

14.

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

15.

Labidi-Galy S, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A . Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 2011; 71(16):5423-34. DOI: 10.1158/0008-5472.CAN-11-0367. View

16.

Liu J, Herold C, Gray K, Penson R, Horowitz N, Konstantinopoulos P . Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 5(12):1731-1738. PMC: 6802049. DOI: 10.1001/jamaoncol.2019.3343. View

17.

Wang Q, Ju X, Wang J, Fan Y, Ren M, Zhang H . Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett. 2018; 438:17-23. DOI: 10.1016/j.canlet.2018.08.028. View

18.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

19.

Dankner M, Gray-Owen S, Huang Y, Blumberg R, Beauchemin N . CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology. 2017; 6(7):e1328336. PMC: 5543821. DOI: 10.1080/2162402X.2017.1328336. View

20.

Dietsch G, Randall T, Gottardo R, Northfelt D, Ramanathan R, Cohen P . Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337). Clin Cancer Res. 2015; 21(24):5445-52. DOI: 10.1158/1078-0432.CCR-15-0578. View